Target Zones and Treatments
Traditional liposuction remains a standard procedure for removal of unwanted fat.In contrast, water-assisted liposuction  (WAL), introduced in the United States less than three years ago, utilizes larger volumes of superwet tumescent anesthesia in small-moderate volume liposuction than that commonly employed by traditional liposuction (TL) in comparable cases.In larger infiltration-volume WAL cases, therefore, potential fluid overloading and lidocaine side-effects can occur as a consequence of technique.Thus, the first purpose of this preliminary report is to compare the infiltration and aspiration volumes, operating and recovery times, urine output rates in surgery and in the recovery period in larger infiltration-volume WAL cases to similar volume cases treated by traditional liposuction. The second purpose is to determine lidocaine levels in plasma and fluids within the subcutaneous space over 24 hours in a separate cohort of two patients undergoing larger-volume WAL procedures.The third purpose is to determine quantitatively by 3D Vector Analysis the significance of the WAL technique on percentages of tissue area reduction within panels on the lower abdomen in three separate patients.
2. Patient and methods
2.1. Study designs
All consented participants underwent either WAL or traditional liposuction procedures under local anesthesia by superwet tumescent infiltration and were offered preoperative oral sedation.An intravenous catheter was inserted in the arm as an access for drugs and intravenous fluid support during the entire surgical procedure and recovery period.The following demographic measurements were obtained prior to surgery:age, weight (kg), height (m), BMI, body fat analysis (Futrex 5500, Futrex Inc., Hagerstown, MD), hematocrit/hemoglobin and blood chemistriesPrior to surgery, patients were encouraged to drink electrolyte-containing fluids
In the first study, patients underwent larger volumes of infiltration by either WAL or traditional liposuction to their abdomens, back rolls, thighs, axillae and brachii to obtain data on 1) total infiltration/aspiration volumes, 2) total lidocaine dose (mg), total lidocaine dosage (mg/kg), and 3) hemodynamic stability and urine output. WAL uses a two-chambered cannula that can independently either channel pulsations of tumescent solution (to loosen the fat and provide anesthesia) or spray pulses of tumescent fluid and simultaneously suction the rinsed, mobilized fatty tissue.Each WAL patient was treated in the three sequential stages. In Phase 1, pulses of tumescent solution [0.05% lidocaine (50ml of 1% lidocaine), 1:1,000,000 epinephrine (1ml of 1:1000 epinephrine), and 20ml 8.4% sodium bicarbonate per liter of 0.9% normal saline] were infused at the lowest rate of 90 ml/minute to provide localized anesthesia, vasoconstriction and tissue rinsing in a non-turgid manner to the planned site(s).During Phase 2, simultaneous suctioning (750mm Hg) and continuous pulsed infiltration, using a tumescent solution containing a reduced 0.025% lidocaine dose, evacuates the fatty tissue and a significant portion of the infusate.In Phase 3, a finishing cannula removes remnants of fatty tissue beneath the dermis with concurrent suctioning and lower rates of pulsed infiltration with 0.025% lidocaine solution. On the other hand, traditional liposuction patients were treated by superwet technique with the same tumescent solution, used in Phase 1 of WAL, prior to liposuction.Volumes (ml) and ratios of infiltration/aspiration/fat, lipocrits and urine output were calculated during and after surgery in the recovery room with each type of liposuction method.
In the second IRB study, two patients participated in the investigation of plasma and subcutaneous fluid lidocaine concentration levels, obtained over twenty-four hours during and after WAL abdominal liposuction, to determine the time and magnitude of peak values.In addition, total infiltration/aspiration volumes, total lidocaine dosage (mg), total lidocaine dosage (mg/kg), and urine output were recorded.Lidocaine concentration levels of plasma and fluid within the subcutaneous spacewere measured by the Emit 2000 Lidocaine Assay (Dade Behring, Inc., Cupertino, CA),a homogeneous enzyme immunoassay technique,based on competition between drug in the sample and drug labeled with recombinant glucose-6-phosphate dehydrogenase for antibody binding sites. Active enzyme converts oxidized nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change measured by spectrophotometric analysis.
In the third study (IRB, controlled, randomized), three patients received randomly assigned treatments of three cumulative phasesof a WAL procedure within 4 x 10cm rectangles on their abdomens, with an additional control panel, listed in Table 1. Standardized photography, weight, body fat analyses, waist and hip circumferences were obtained at baseline and three months after treatment.Tissue reduction was assessed by using the Vectra 3D Software System (Canfield Scientific, Fairfield, NJ), that identified the permanent India ink markers around corners of each targeted site and calculated changes in horizontal, diagonal and perimeter baseline measurements compared to findings at three months.At the completion of the study, total abdominal liposuction was performed on each subject to achieve a final aesthetic result.
Study 1.As shown in Table 2, twelve WAL patients (8 females; 4 males) with an ASA I classification underwent large infiltration volume and fat aspiration.Participants averaged a mean age of 49.0 years (range 29-61 years), mean weight of 71.1kg (range 51.7-98.9 kg), mean height of 1.7 meters (range 1.3-1.9 meters), mean body mass index of 25.2 (range 21.0 -30.2), and mean body fat of 31.9% (range 23.0-35.0%).As summarized in Table 3, thirteen TL patients (10 females; 3 males) with an ASA I classification underwent large infiltration volume and fat aspiration.This group of patients averaged a mean age of 53.3 years (range 32-63 years), mean weight of 77.5kg (range 67.1-94.3kg), mean height of 1.7 meters (range 1.5-1.9 meters), mean body mass index of 27.4 (range 24.0-30.3), and mean body fat of 33.7% (range 27.8-36.4%).
|2||Phase 1: InfiltrationSolution (25ml)|
(25 cannula passes)
|3||Phase 1: Infiltration Solution (25ml)|
(25 cannula passes)
Phase 2: Simultaneous Suctioning (100ml) and Infiltration (225ml)
(25 cannula passes)
|4||Phase 1: 25ml Infiltration Solution (25 cannula passes)|
Phase 2: Simultaneous Suctioning (100ml) and Infiltration (225ml)
(25 cannula passes)
Phase 3: Simultaneous Suctioning(25ml) and Infiltration (50ml)
(10 cannula passes)
WAL patients received almost all their total fluid support from infiltration solutions which served as their anesthetic solution, maintenance fluid, and volume replacement fluid (Table 2).The average total subcutaneous infiltration volume was measured at 6239ml (range 4920-7500ml), while the average aspiration volume was calculated at 5460ml (range 4350-6900ml). The average infiltration-to-aspiration ratio was 1.2:1 (range 1.1:1-1.3:1).The average volume of aspirated fat was 2456ml (range 1716-3105ml), which calculated to an average infiltration-to-fat ratio of 2.6:1 (range 2.2:1-3.0:1) and an average fat-to-aspirate percentage of 44.9% (range 37.6-56.2%).During surgery, patients received an average total lidocaine dose of 1702mgs (range 1423-2095mgs) and an average lidocaine dosage of 24.2mg/kg (range 18.9-33.6mg/kg)
In contrast, TL patients received their total fluid support both from the infiltration tumescent solution and intravenous saline fluid resuscitation (Table 3).The average total subcutaneous infiltration volume was measured as 5350ml (range 4500-6500ml), while the average aspiration volume was calculated at 5042ml (range 4000-6000ml).The average infiltration-to-aspiration ratio was 1.1:1 (range 1.0:1-1.1:1). The average volume of aspirated fat was 4036ml (range 3280-4800ml), which calculated to an average infiltration-to-fat ratio of 1.3:1 (range 1.2-1.6) and an average fat-to-aspirate percentage of 80.2% (range 70.0-86.0%).During surgery, patients received an average total lidocaine dose of 2675mg (range 2450-3100mg) and an average lidocaine dosage of 34.8mg/kg (range 27.0-40.9mg/kg).
|Total Infiltration(ml)||Total Aspiration(ml)||I/A|
|Pt||Age||Wt (kg)||Ht (m)||BMI||Total Lido (mg)||Lido Dosage (mg/kg)||Total Infiltration (ml)||Total Aspiration|
|I/A Ratio*||Total Fat (ml)||I/F|
The average operating time for the larger volume WAL group was 4.0 hours (range 3.0-5.0 hours), while the average time in the recovery room was 1.4 hours (Table 4). The average tumescent infiltration fluid rate was 24.8ml/kg/hr (range 13.1-38.8 ml/kg/hr).The average urine output in surgery was 1.8 ml/kg/hr (range 1.3-2.5 ml/kg/hr), while the average urine output in the recovery room was 2.2ml/kg/hr (range 1.5-2.7ml/kg/hr).As cited in Table 5, similar data was obtained from the larger volume TL patients who demonstrated an average operating time of 3.5 hours (range 3.0-4.0 hours) and an average recovery time of 1.3 hours (range 1.0-1.5 hours).The average tumescent infiltration fluid rate during surgery was 20.4ml/kg/hr (range 15.5-27.0ml/kg/hr).The average urine output in surgery was 2.0ml/kg/hr (range 1.3-2.7ml/kg/hr), while the average urine output in the recovery room was 2.1mlkg/hr (range 1.7-2.4ml/kg/hr).The majority of patients were monitored for over 12 hours after surgery.
|Pt #||OR Time|
|Recovery Time OR|
|Infiltration Fluid Urine Output Rate|
During SurgeryDuring Surgery
|Recovery Room Urine Output|
In both WAL and TL groups, lipocrits of less than 1.0% were estimated from millimeters of red blood cell presence and millimeters of non-red blood cell containing fluid from aspirates measured within centrifuged capillary tubes from final aspirates in each patient. Preoperative hematocrit, hemoglobin, electrolytes, blood urea nitrogen/creatinine and liver function test levels demonstrated no significant changes from their 3-month postoperative values.During surgery and the perioperative period, episodes of tachycardia, hypotension, excessive bleeding, dyspnea/wheezing, significant detectable fluid shifts, pulmonary edema, congestive heart failure, or low urine output were not observed.Each patient was assessed to be stable hemodynamically throughout the entire procedure and in the recovery period.
None of the TL or WAL patients developed in the immediate postoperative period or after 6-month follow-ups infections, deep venous thrombosis or skin loss.Subjective assessments of postoperative pain suggest that WAL patients on an individual basis experienced less pain and discomfort and were able to resume normal pre-surgical activities more rapidly than TL patients.There were no significant differences in the low incidences of ecchymoses, surface irregularities and nodular fibroses between the two treatment groups.
|Recovery Time OR|
|Parenteral and Infiltration FluidUrine Output Rate(ml/kg/hr)Rate (ml/kg/hr)|
During SurgeryDuring Surgery
|Recovery Room Output|
Study 2. Two female subjects with an ASA I classification volunteered for lidocaine levels in plasma and fluid within the subcutaneous spaceduring and after liposuction of their abdomens. The following demographic measurements from subject 1 and subject 2 were obtained, respectfully:age (33yr, 47yr), height (1.7m, 1.6m), weight (78.6Kg, 59.0Kg), body fat (38.3%, 36.0%), and BMI (27.2, 23.9).For each respective subject,the totaltumescent infiltration volumes (5900ml, 3050ml), final aspiration volumes (5500ml= 750ml fat + 4750ml infranate); 3050ml = 575ml fat + 1875ml infranate), total lidocaine doses (1700mg, 975mg), and lidocaine dosages (29.5mg/kg, 12.5mg/kg2) were tabulated.In subject 1, the average tumescent infiltration fluid rate was 25.0ml/kg/hr, while the average urine output during surgery and in the recovery room was 1.5ml/kg/hr.In subject 2, the average tumescent infiltration fluid rate was 17.2ml/kg/hr, while the total urine output was 2.1ml/kg/hr.Serial lipocrits were calculated less than 1.0% of infranates collected from each subject.Preoperative blood work demonstrated no significant changes from 3 month post-operative values.During surgery and postoperative recovery period (average 3 hours), subjects did not exhibit any deleterious signs or symptoms that could be attributed to lidocaine toxicity or fluid overload.Patients received no parenteral fluid support other than tumescent infiltration and were observed to be hemodynamically stable throughout the office procedure and continued recovery at home.
Lidocaine concentrations in plasma and fluids with the subcutaneous space were measured by enzyme immunoassay technique and plotted by connecting the sequential levels for a continuous curve over 24 hours (Figure 1).The peak occurrence of the peak plasma lidocaine concentration, were observed at about 9 hours in both subjects.At 30 minutes, elevated plasma levels were measured at 0.5-0.1µg/ml, gradually rising to peak levels between 0.80-0.95µg/ml, and falling to 0.30µg/ml at 24 hours.All recorded plasma levels were lower than elevated levels from subcutaneous fluids within the tumescent-treated abdomens measured between 1-1 ½ hours (95-130ug/ml) and after 6-8 hours (66-95µg/ml) from the start of lidocaine infiltration.
Study 3.Three female patients with ASA I classifications had an average age of 46 years (range 26-66 years).Each patient’s pretreatment weight, percent body fat, BMI, and hip circumference did not vary significantly from the measurements 3 months after surgery.In each subject, a reduction in waist circumference from baseline to 3 months was observed (Table 6).
Results of surface area changes from baseline to 3 months within the four isolated rectangles, as determined by Vectra 3D analysis, are shown in Figure 2.Each target panel received cumulative components of the standard treatment protocol for a WAL procedure.At the three month evaluation period, the difference in mean percent area of tissue reduction between panel 1 (control) and panel 2 (subcutaneous infiltration) was negligible.However, the increases in mean percent area of tissue reduction, observed in panel 3 (6.8%) and in panel 4 (6.7%) over control (0.0%) and panel 1 (1.2%), indicate that the removal of fat facilitates increased the accommodation, retraction or contraction of the overlying skin.
|% Body Fat||Body Mass Index||Waist Circum.(cm)||Hip Circum. (cm)|
|0 mos||3 mos||0 mos||3 mos||0 mos||3|
Traditional liposuction continues to be the gold standard to remove fat and contour body shapes.Since 1986, advocatespreferred either a superwet [15-17] [28-31] or a tumescent technique[2-8] , each of which have established proven safety and efficacy profiles using similar anesthetic solutions, but with significantly differing ratios of infiltration volume to total aspiration volumes.Each technique appears to be safe when strict clinical criteria[11-14] are observed such as selecting ASA I patients, using less than 5 liters of dilute volumes of lidocaine and epinephrine for average cases, limiting total lipoaspirates to less than 5 liters in the outpatient setting, respecting the safe maximum 35mg/kg of lidocaine, and prolonging patient discharge for large volume cases because of various factors delaying peak lidocaine levels as late as 10 to 15 hours.In particular, safer outcomes have been reported when the physiologic impact of larger volume liposuction is understood in cases that are associated with significant fluid shifts, third space losses, and potential epinephrine and lidocaine side-effects and toxicities.
In larger cases, superwet technique[28-31] is usually associated with the use of parenteral fluid maintenance and replacement with total intravenous or general anesthesia, while Klein’s tumescent technique   recommends the elimination for parenteral fluid support or total intravenous/general anesthesia in large volume cases.With either technique, however, the issue of absorption of the tumescent fluid infiltrate is complicated by the removal of the infiltrate along with fat and blood during suctioning.Since most of the infiltrate, ranging from 22-29 percent, is not removed by suctioning, at least 70 percent of the infiltrate is believed to remain after the procedure .Fluid overload   [51-53] becomes possible whenever substantial amounts of tumescent infiltrative fluids or parenteral fluids are used in high volume cases with the tumescent (3-4:1 ratio) and superwet (1- 1.5:1) techniques.Since WAL’s variable force infusion pump pulses fan-shaped jets of tumescent solution into the subcutaneous fatty tissue during its three procedural phases, but only suctions simultaneously the loosened fat and fluid during the latter two phases, the final physiological and pharmacological impact is expected to reflect more closely the infiltration-to-aspiration ratios (between 3-4:1) observed with the tumescent technique.The author’s recent WAL publication provided, however, evidence to the contrary by recording an average 1.1:1 infiltration to aspiration ratio in fifty small-moderate infiltration volume cases.
Although the present study 1 data was underpowered for statistical significance, the observed results indicated that WAL and TL exhibited a comparative safety margin in similar types of cases for larger volumes of infiltrated tumescent solution, lipoaspiration, and fat removal, respectfully: average total infiltration (WAL, 6239ml; TL, 5350ml); total aspiration (WAL, 5460ml; TL, 5042ml, and total fat (WAL, 2456ml; TL, 4036ml).In these cases, the average calculated infiltration-to-aspiration ratios were similar (WAL, 1.2:1; TL, 1.1:1), approaching that observed in typical cases using superwet technique (1-1.5:1) rather than that experienced with the Klein tumescent technique (3-4:1).Although explanations for WAL’s findings as a superwet technique are unclear, the data suggest that simultaneous infiltration- aspiration for the greater part of the procedure in phases 2 and 3 may account for the observed balanced I/A ratio, as found with TL procedures.In this study, the use of WAL, however, resulted in a
lower average fat-to-aspiration ratio (44.9%) than that observed with TL (80.2%) or with other devices [19-21]    that commonly experience 70-90% fat-to-aspiration ratios in comparable volume cases.These findings suggest that WAL may be more inefficient in removing more fibrous fat from the back rolls and upper abdomen than TL.
In this study, the average total lidocaine dose was larger in TL patients (2675mg) than in WAL patients(1702mg) because of higher concentrations delivered during the entire procedure in TL patients (0.05% lidocaine, average 5350ml total tumescent infiltration) than in WAL patients ( phase 1, 0.05%; phases 2-3, 0.025% lidocaine, average 6239ml total tumescent infiltration).For similar reasons, the lidocaine dosage exposure was greater in the TL patients (34.8mg/kg) than in WAL patients (24.2mg/kg).
Although the average tumescent fluid infiltration volume (24.8ml/kg/hr) in the WAL patients provided the only fluid replacement, urine output safely averaged about 1.8 ml/kg/hr during surgery and 2.2ml/kg/hr in the postoperative recovery period.In the TL patients, the average tumescent fluid infiltration volume (5350ml) was augmented by parenteral intravenous fluid support (average 1000ml ringer’s lactate) for a total infiltration fluid rate of 20.4ml/kg/hr during surgery to maintain an average urine output rate of 2.0ml/kg/hr in surgery and 2.1ml/kg/hr in the recovery room.In both procedures, clinical parameters of fluid overload (pulmonary edema, dyspnea, wheezing, congestive heart failure), low maintenance fluid replacement (tachycardia, hypotension, low urine output), and significant blood loss attributable to the procedure were not observed.In larger infiltration volume WAL or TL cases, however, patients must be provided with an available intravenous access site, be the recipient of prewarmed tumescent fluids, supported by a warming blanket and an anti-embolic calf/ankle pumps, and monitored fluid outputs with a urinary catheter.The information from this limited comparison of techniques does not significantly add to previously published data    , but confirms the safety profile during larger infiltration and liposuction cases under local anesthesia.Along with sound clinical judgment, both techniques may be performed safely under strict preoperative criteria, intraoperative fluid monitoring, and postoperative assessments for at least 12 hours.Overnight stays are recommended for monitoring of vital signs and fluid resuscitation in larger volume cases.
The pharmacokinetics of dilute amounts of lidocaine  , approaching 35mg/kg, and epinephrine into subcutaneous fat with relatively large volumes of fluid have been found to be safe with the tumescent technique because of slow absorption of lidocaine in the presence of epinephrine, poor vascularity of fatty tissue, and the removal of a variable amount of much of the infused lidocaine by suction before systemic absorption.In studies[21-27]  associated with high dosages, peak serum levels below toxic levels of 5µg/ml were measured about 10-12 hours after infiltration.In the second part of this study, the lidocaine dosages used in the two patients were calculated at 12.5mg/kg and 29.5mg/kg, exceeding the recommended the safe limit of lidocaine dosage of 7mg/kg with epinephrine in normal healthy adults , but below the estimated maximal safe dosage of 35mg/kg, as recommended in the Klein tumescent technique.The low plasma peak levels between 0.80-0.95µg/ml at 9 hours and the elevated subcutaneous fluid levels from lipoaspirates at 1-1 ½ hours (95-130µg/ml) and after 6-8 hours (66-95µg/ml) from the start of lidocaine infiltration were consistent and similar with those observed in previous cited publications. These results confirm the relative safeness of using larger infiltration volumes with simultaneous liposuction during the WAL technique.Because of costs, the study was limited to few patients and used an enzyme immunoassay technique that was unable to measure the variability in protein binding and active metabolites of lidocaine (monoethylglycinexylide and glycinexylidide) , which can be over 80% active and contribute to lidocaine toxicity.Although no significant side effects have been reported with higher lidocaine dosages , further expanded clinical and laboratory studies need to be performed to determine the optimal lidocaine dose for WAL to provide complete local anesthesia.
Although the number of patients in third part of the study is small for statistical significance, the observed results indicated tissue accommodation after WAL treatments.In younger patients who present with minimal laxity to the overlying skin, the removal of fat can be expected to result in normal skin retraction, as observed in panels 3 and 4.There exists no evidence from this study that this beneficial finding was due to the preservation of the septal architecture.In the future, one of the challenges for WAL, as with other energized liposuctiondevices[42-47], is to investigate the contribution of energy in the form of mechanical or thermal injury to improve tissue reduction/contraction in the skin-challenged patient.Their limited clinical benefit brings into perspective the cost-benefit value of thermally-equipped devices for tissue tightening and emphasizes the need for further clinical research and applications.
In conclusion, we believe that larger-volume liposuction is safe and efficacious by WAL compared to TL, provided attention is directed to tumescent anesthesia, fluid replacement and overload, blood loss and postoperative monitoring for potential lidocaine side-effects.
On the basis of our limited and preliminary study, patients undergoing WAL procedures, as well as TL procedures, are safe for cases involving larger infiltration/aspiration volumes that introduce the possibility of lidocaine side-effects and toxicities and fluid imbalance. Patients did not experience significant adverse events in this study.Specifically, this brief study demonstrated that current algorithm with WAL treatments results in peak plasma lidocaine levels between 0.80-0.95ug/ml around 9 hours when subcutaneous fluid levels were elevated around 95-130ug/ml at 1-1½ into surgery and 66-95µg/ml at 6-8 hour after lidocaine infiltration.Although the correlation between total plasma lidocaine concentration (<5µg/ml) and the predictability of specific toxicity is tenuous at best and can lead to false sense of security, the surgeon must always be mindful of careful clinical monitoring during and at least 24 hours after completion of the procedure.In addition, preliminary results, indicating a small but positive trend for skin reduction by Vectra 3D analysis, remain underpowered for significance and will require larger number of patients for statistical validation.
The authors thank Dennis DaSilva, Canfield Scientific (Fairfield, New Jersey) for Vectra 3D analysis,Erica Lopez Ulloa and Margaret Gaston, BS for clinical and statistical assistance.
Illouz Y. 1983Body contouring by lipolysis: A 5-year experience with over 3000 cases.Plast ReconstrSurg 72 591 597
Klein J. 1987Tumescent technique.Am J Cosm Surg; 4 263 267
Klein J. A. 1988Anesthesia for liposuction in dermatologic surgery.J Derm Surg Oncol; 14 1124 1132
Lillis P. J. 1988Liposuction surgery under local anesthesia: Limited blood loss and minimal lidocaineabsorption.J Derm Surg Oncol; 14 1145 1148
Bernstein G. Hanke C. W. 1988Safety of liposuction: A review of 9478 cases performed by dermatologists.J Dermatol Surg Oncol; 14 1112 1114
Klein JA. 1990The tumescent technique: Anesthesia and modified liposuction technique.DermatolClin; 8 425 437
Lillis PJ. 1990The tumescent technique for liposuction surgery.Dermatol Clin; 8 439 450
Hanke C. W. Berstein G. Bullock S. 1995Safety of tumescent liposuction in 15,336 patients.DermatolSurg; 21 459 461
Fodor PB, Watson JP. 1999Wetting solutions in ultrasound-assisted lipoplasty.Clin in Plast Surg; 26 289 293
Habbema L. 2009Safety of liposuction using exclusively tumescent local anesthesia in 3,240consecutive cases.Dermatol Surg; 35 1728 1735
Morello D. Colon G. Fredricks S. et al. 1997Patient safety in accredited office surgical facilities.Plast Reconstr Surg; 99 1496 1500
Haeck PC, Swanson JA, Iverson RE, et al. 2009Evidence-based patient safety advisory: Patientselection and procedures in ambulatory surgery.Plast Reconstr Surg; 124:6S-27S.
Haeck PC, Swanson JA, Gutowski KA, et al. 2009Evidence-based patient safety advisory:Liposuction.Plast Reconstr Surg; 124:28S-44S.
Lipschitz A. H. Kenkel J. M. Luby M. et al. 2004Electrolyte and plasma enzyme analyses during large volume liposuction.Plast Reconstr Surg; 114 766 775discussion 776-777.
Rohrich RJ, Kenkel JM, Janis JE, et al. 2003An update on the role of subcutaneous infiltration insuction-assisted lipoplasty.Plast Reconstr Surg; 111:926.
Basile A. R. Fernandes F. Basile V. et al. 2006Fluid resuscitation in liposuction: A prospective analysisof infiltration-to-total aspirate ratios lower than used for the superwet technique.Aesth PlastSurg; 30 659 665
Pitman GH, Aker JS, Tripp ZD. 1996Tumescent liposuction: A surgeon’s perspective.Clin Plast Surg; 23 633 641discussion 642-645.
Meister F. 1996Possible association between tumescent technique and life-threatening pulmonary complications.Clin Plast Surg; 23 642 645
Karmo F. R. Milan M. F. Silbergleit A. 2001Blood loss in major liposuction procedures:A comparisonstudy using suction-assisted versus ultrasonically assisted lipoplasty.Plast Reconstr Surg; 108; 241.
Samdal F. Amland P. F. Bugge J. F. 1995Blood loss during suction-assisted lipectomy with largevolumes of dilute adrenaline.Scand J Plast Reconstr Surg Hand Surg; 29 161 165
Klein JA. 1990Tumescent technique for regional anesthesia permits lidocaine doses of 35mg/kg for.liposuction.J Dermatol Surg Oncol; 16:248.
Samdal F. Amland P. F. Bugge J. F. 1994Plasma lidocaine levels during suction-assisted lipectomy using large doses of dilute lidocaine with epinephrine.Plast Reconstr Surg; 93:1217.
Klein J. A. Kassarjdian N. 1997Lidocaine toxicity with tumescent liposuction: A case report of drug interactions.Dermatol Surg; 23:1169.
Hagerty T. Klein P. 1999Fat partitioning of lidocaine in tumescent liposuction.Ann Plast Surg; 42 372 375
Burk R. W. I. I. I. Guzman-Steiin G. Vasconez L. O. 1996Lidocaine and epinephrine levels in tumescent technique liposuction.Plast Reconstr Surg; 97 1379 1384
Brown Sa. Lipschitz A. H. Kenkel J. et al. 2004Pharmacokinetics and safety of epinephrine use inliposuction.Plast Reconstr Surg; 114:756.
Nordstrom H. Stange K. 2005Plasma lidocaine levels and risks after liposuction with tumescentanesthesia.Acta Anaesthesiol Scand; 49 1487 1490
Trott S. Beran S. Rohrich R. J. et al. 1998Safety considerations and fluid resuscitation in liposuction; Ananalysis of 53 consecutive patients.Plast Reconstr Surg; 102 2220 2229
Kenkle J. M. Lipschitz A. H. Luby M. et al. 2004Hemodynamic physiology and thermoregulation inliposuction.Plast Reconstr Surg; 114:503.
Rohrich R. J. Leedy J. E. Swamy R. et al. 2006Fluid resuscitation in liposuction:A retrospective reviewof 89 consecutive patients.Plast Reconstr Surg; 117 431 435
Commons G. W. Halperin B. Chang C. C. 2001Large volume liposuction: A review of 631 consecutivecases over 12 years.Plast Reconstr Surg; 108 1753 1763discussion 1764-1767.
Naguib M. MM Magboul Samarkandi. A. et al. 1998Adverse effects and drug interactions associatedwith local and regional anesthesia.Drug Saf.; 18 221 225
Lehnhardt M. Homann H. H. Daigeler A. et al. 2008Major and lethal complications of liposuction: Areview of 72 cases in Germany between 1998 and 2002.Plast Reconstr Surg; 121:396e- 403e.
Heymans O. Castus P. Grandjean F. X. Van Zele D. 2006Liposuction: Review of the techniques,innovations and applications.Acta chir belg; 106 647 653
Mann MW, Palm MD, Sengelmann RD. 2008New Advances in Liposuction Technology.Semin Cutan Med Surg; 27 72 82
Taufiz A. Z. 2006Water-jet-assisted liposuction. In: Shiffman MA, Di Giuseppe A, editors.Liposuction:Principles and Practice.New York: Springer-Verlag;; Chapter 49, 326 330
Stutz J. Krahl D. 2008Water jet-assisted liposuction for patients with lipoedema: Histologic andimmunologic analysis of the aspirates of 30 lipoedema patients.Aesth Plast Surg; June.
Wanner M. Jacob S. Schwarzl F. Honigmann K. Oberholzer M. Pierer G. 2001Wasser-jet dissection imfettgewebe.Swiss Surg; 7 173 179
Sasaki G. H. 2011Preliminary Report: Part 1.Water-Assisted Liposuction (WAL) for body contouring and lipo-harvesting: Safety and Efficacy with 50 consecutive patients.Aesthetic Plastic Surgery Journal.Spring Issue,.
Gilman AG, Goodman LS, Rall TW, et al. 1985Goodman and Gilman’s The Pharmacologic Basis ofTherapeutics, 7th Ed.New York: Macmillan,:310.
Grazer FM, Meister FL. 1997Factors contributing to adverse effects of the tumescent technique.Aesth Surg J; 17 411 413
Scheflan M. Tazi H. 1996Ultrasonically assisted body contouring.Aesth Surg J; 16 117 122
Prado A. Andrades P. Danilla S. et al. 2006A prospective, randomized, double-blind, controlledClinical trial comparing laser-assisted lipoplasty with suction-assisted lipoplasty.Plast Reconstr; 118 1032 1045
Di Bernardo B. E. Reyes J. Chien B. 2009Evaluation of tissue thermal effects from 1064/1320-nm laser-assisted lipolysis and its clinical implications.J Cosm Laser Ther; 11 62 69
Di Bernardo B. E. Reyes J. 2009Preliminary report: evaluation of skin tightening after laser-assistedliposuction.Aesth Surg J; 29 400 408
Sasaki G. H. Tevez A. 2009Laser-assisted liposuction for facial and body contouring and skin tightening:A 2-year experience with 75 consecutive patients.Sem Cut Med Surg; 8 226 235
Sasaki G. H. 2010Preliminary report: Quantification of human abdominal tissue tightening and contraction after component treatments with 1064nm/1320nm laser-assisted lipolysis: Clinical implications.Aesth Surg J; 30 239 245Commentary: Jewell M, 246-248.
Goldman A. Gotkin R. H. DS Sarnoff et. al 2008Cellulite: A new treatment approach combiningsubdermal Nd:YAG laser lipolysis and autologous fat transplantation.Aesth Surg J; 28 656 662
Pitman GH, Aker JS, Tripp ZD. 1996Tumescent liposuction.Clin Plast Surg; 23:633.
Rohrich RJ, Beran SJ, Fodor PB. 1997The role of subcutaneous infiltration in suction-assistedlipoplasty: A review.Plast Reconstr Surg; 99:514.
MD Gilliland Coates. N. 1989Tumescent liposuction complicated by pulmonary edema. Plast Reconstr Surg; 99:215.
Pitman GH. 1993Tumescent technique for local anesthesia improves safety in large-volume liposuction (Discussion).Plast Reconstr Surg; 92:1099.
Fodor PB. 1995Wetting solutions in aspirate lipoplasty: A plea for safety in liposuction (Editorial). Aesth Plast Surg; 19:379.
Maxwell GP, Gingrass MK. 1998Ultrasound-assisted lipoplasty: A clinical study of 250 consecutivepatients.Plast Reconstr Surg; 101:189.
Klein J. A. 1990Tumescent technique for regional anesthesia permits lidocaine doses of 35 mg/kg for liposuction.Dermatol Surg Oncol; 16:248.